null

APC Anti-Human CD274/PD-L1 Antibody [29E.2A3] (AGEL1650)

SKU:
AGEL1650
Product Type:
Antibody
Antibody Type:
Monoclonal Antibody
Reactivity:
Human
Applications:
FC
€219 - €579
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

APC Anti-Human CD274/PD-L1 Antibody [29E.2A3]

The Human CD274 (PD-L1) Monoclonal Antibody (APC Conjugated, 29E.2A3) is a cutting-edge tool for researchers delving into the role of the PD-L1 protein in immune regulation and cancer biology. This monoclonal antibody, conjugated with APC for enhanced detection capabilities, specifically targets human CD274 (PD-L1) and is validated for use in flow cytometry applications. By binding to PD-L1, this antibody enables precise detection and analysis of PD-L1 expression in diverse cell types, making it an invaluable resource for investigations in immunology and oncology.PD-L1, a checkpoint protein known for its role in immune evasion and suppression, is a critical molecule in the regulation of immune responses and the maintenance of immune tolerance. Its involvement in immune checkpoint pathways has positioned PD-L1 as a key target for research aimed at understanding and manipulating anti-tumor immune responses.

By elucidating the functions and interactions of PD-L1, researchers can gain insights into cancer immunotherapy and develop strategies to enhance immune responses against tumors while limiting autoimmune reactions.The Human CD274 (PD-L1) Monoclonal Antibody (APC Conjugated, 29E.2A3) serves as a powerful tool for investigating the complex interplay between PD-L1 expression and immune regulation in various disease contexts, particularly cancer. Its specificity, sensitivity, and reliable performance in flow cytometry make it an essential component of studies aiming to deepen our understanding of PD-L1 biology and explore innovative therapeutic approaches targeting the PD-1/PD-L1 axis. Unlock the potential of PD-L1 research with this advanced antibody and pave the way for novel insights into immune modulation and cancer immunity.